SlideShare a Scribd company logo
1 of 15
Download to read offline
The Spanish Biotech sector in figures


                                  Juan Carlos Cortés

                               International Director
               Centre for the Development of Industrial Technology
                     Ministry of Economy & Competitiveness


UNIÓN EUROPEA
Fondo Europeo de
Desarrollo Regional (FEDER)   1           (07/02/2013)
Una manera de hacer Europa
The Spanish Biotech sector

•           A young sector, 15 years old.
•           Internationalization is part of its DNA.
•           Success depends on the capacity to export.
•           Crucial: joint projects and technology exchange
            agreements.

     Spain:
     • Biotech industry growth in the last four years 350%
     • A key player in R&D, spin-offs, research and
       collaboration.
     • Biotech: a key sector in the knowledge economy

    UNIÓN EUROPEA
    Fondo Europeo de
    Desarrollo Regional (FEDER)   2   (07/02/2013)
    Una manera de hacer Europa
The Spanish Biotech sector now
                                                                      Source: Genoma España/ASEBIO


• Nº enterprises:                                           1.715 (617 EB+1.098 EIB)
• Nº personnel employed EB1+EIB2: 163.526
• Estimated turnover EB (2010):                             60.122 MM€
• Internal expenditures in R&D:                             568.280 M€ (11,2% increase from
  2009)
• Enterprises related to human health:                             67%
• Enterprises related to agro-food:                                23%
• Enterprises related to industrial processing: 10%
1EB:   biotechology enterprise
2EIB:industrial commercial or services’ enterprise, with interests, develpments and products in
biotechnology
    UNIÓN EUROPEA
    Fondo Europeo de
    Desarrollo Regional (FEDER)   3          (07/02/2013)
    Una manera de hacer Europa
Contribution of Biotechnology to
 the Spanish economy

Contribution to
GDP 2010 (%)

1,2
                                        GDP Contribution

                                        Employment


                                        Macroeconomic impact of biotechnology
OECD prediction
GDP 2030 (%)

2,7
    Contribution to GDP (%)

    Predicted contribution to GDP (%)

    Employment

    Predicted employment
    UNIÓN EUROPEA
    Fondo Europeo de
    Desarrollo Regional (FEDER)   4                   (07/02/2013)
    Una manera de hacer Europa
Classification of Bio-companies

                                              Agriculture



                            Food                                   Animal Health




                                Environment                    Human Health
  UNIÓN EUROPEA
  Fondo Europeo de
  Desarrollo Regional (FEDER)            5      (07/02/2013)
  Una manera de hacer Europa
Profile of the Biotechnology enterprise (EB) in
Spain

   •            Between 10 and 20 employees

   •            Over 80% of the staff university graduates

   •            Over 25% of the staff devoted to R&D

   •            Less than 5 years of activity

   •            Located mostly in Madrid, Barcelona, Andalucía, País Vasco and Valencia

   •            Linked to prestigious public research institutions



       UNIÓN EUROPEA
       Fondo Europeo de
       Desarrollo Regional (FEDER)   6              (07/02/2013)
       Una manera de hacer Europa
Spain: eight Bioregions




UNIÓN EUROPEA
Fondo Europeo de
Desarrollo Regional (FEDER)   7   (07/02/2013)
Una manera de hacer Europa
The Spanish Biotech sector :
   scientific production (00-08)
                                                                                  Source: Genoma España
European contribution to world scientific production        European contribution to world scientific
in biosciences (2000)                                       production in biosciences (2008)


United Kingdom                                                     Germany
      Germany                                                United Kingdom
        France                                                       France
            Italy                                                      Italy
   Netherlands                                                        Spain
         Spain                                                  Netherlands
       Sweden                                                       Sweden
      Belgium                                                      Denmark
      Denmark                                                      Belgium
       Finland                                                      Austria
       Austria                                                      Finland
       Ireland                                                     Portugal
      Portugal                                                      Ireland
       Greece                                                       Greece
   Luxembourg                                                   Luxembourg

        UNIÓN EUROPEA


                                      Growth: 47% (annual rate 6%)
        Fondo Europeo de
        Desarrollo Regional (FEDER)         8          (07/02/2013)
        Una manera de hacer Europa
The Biotech sector in Spain:
evolution of the nº of enterprises (00-08)
                                                    Source: Genoma España

  Evolution of EB and EIB




   UNIÓN EUROPEA
   Fondo Europeo de
   Desarrollo Regional (FEDER)   9   (07/02/2013)
   Una manera de hacer Europa
The biotech sector in Spain: total
public expenditures on R&D&I biotech
                                                    Source: Genoma España

Total public support for R&D&I in Biotechnology (Mio €)




  UNIÓN EUROPEA
  Fondo Europeo de
  Desarrollo Regional (FEDER)   10   (07/02/2013)
  Una manera de hacer Europa
Success stories

- 2000: Pfizer invested 12m euros in its European Biometric Centre, which has
support functions for the rest of Europe and USA.
- 2002: Abengoa signed a 35.5million dollar R&D Agreement with the US
Department of Energy.
- 2002: Lilly opened its research centre for medicinal chemistry, one of the
biggest in the world, investing 20 million euros.
- 2003: Serono concentrates its global growth-hormone production in Spain.
- 2005: GSK opens its research centre for tropical diseases in Spain.
- 2009: Genzyme sets up a sales office in Madrid and has a warehouse for
domestic distribution.
- 2011: Celgene opens its first research centre outside the USA in Seville. The
Celgene Institute of Translational Research Europe (CITRE) plans to focus on
advanced therapies and regenerative medicine.



   UNIÓN EUROPEA
   Fondo Europeo de
   Desarrollo Regional (FEDER)   11   (07/02/2013)
   Una manera de hacer Europa
Spanish Technology Platforms




 • Biotech Markets
 • Nanomedicine www.nanomedspain.net/
 • Innovative Medicines www.medicamentos-
   innovadores.org/
 • Plants Biotechnology www.invigen.org
 • Animal Health www.vetmasi.es



  UNIÓN EUROPEA
  Fondo Europeo de
  Desarrollo Regional (FEDER)   12   (07/02/2013)
  Una manera de hacer Europa
CDTI DATA 2011

           RTD Project         Nr .of funded    CDTI funding   Total
           and NEOTEC          companies                       investment
                               92               M€48,116       M€ 64,6



           INNPRONTA           Nr. of funded    CDTI funding   Total
           call                companies                       investment
             (2 Projects)      17               M€ 27,67       M€ 32,56


            Indo-Spanish       Nr. of proposals Selected
            call CDTI-DBT                       projects
            First call 2012    7                3



 UNIÓN EUROPEA
 Fondo Europeo de
 Desarrollo Regional (FEDER)   13              (07/02/2013)
 Una manera de hacer Europa
Potential areas for cooperation
SPANISH TECHNOLOGICAL STRENGTHS
                                                                                Health and Nano biotechnology

               Some Developments in 2011
                  •         Oncology,: Advancell, GP Pharm, Ingenasa, Pharmamar, IUCT, Lipopharma, Entrechem,
                            Orizon Genomics
                  •         Cardiology/ Neurological: Neuron Pharma, Sanifit,
                  •         Oftalmology: Sylentis, Proretina Therapeutics, Biotechnology Institute, Bioftalmic
                  •         Vaccines: Archivel Farma, Ferrer, Rovi, Leti
                  •         Biotech diagnosis, biomarkers, nanomedicine: Orizon Genomics, Sistemas Genomicos, AB
                            BIOTICs, Genomica, Biobide, Pangaea Biotech, Genetadi Botech, Aromics, Nanotherapy,
                            Nanoinmunotech…
                  •         Animal Health: Bionaturis, Ingenasa
                  •         Bioinformatic: Integromics, Noray Bio, Biomol Informatics
                  •         Regenerative medicine, Cell and Gene therapy: Tigenics (former Cellerix)
                  •         Biofuels: Abengoa, Repsol
               4th Nano biotechnology Scientific production in the world
                  •         Barcelona the 2nd Nano biotech city (1st Boston)



  UNIÓN EUROPEA
  Fondo Europeo de
  Desarrollo Regional (FEDER)               14                   (07/02/2013)
  Una manera de hacer Europa
Institutions supporting the sector in Spain:
Promoting value creation through knowledge


                                          www.asebio.com


   •          ASEBIO is the Spanish Asociation of Biocompanies
   •          ASEBIO belongs to and is supported by EUROPABIO, and is a part of CEOE
              and SEBBM




       UNIÓN EUROPEA
       Fondo Europeo de
       Desarrollo Regional (FEDER)   15       (07/02/2013)
       Una manera de hacer Europa

More Related Content

Similar to Cdti biotech spain_juan_carlos_cortes

Vertigeen stardard project presentation v final
Vertigeen stardard project presentation v finalVertigeen stardard project presentation v final
Vertigeen stardard project presentation v final
Adriana Rodriguez Diaz
 
Vertigeen stardard project presentation v final
Vertigeen stardard project presentation v finalVertigeen stardard project presentation v final
Vertigeen stardard project presentation v final
Adriana Rodriguez Diaz
 
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14
Aurore Beaume
 
Genopole Crete Sept14 2007
Genopole  Crete Sept14 2007Genopole  Crete Sept14 2007
Genopole Crete Sept14 2007
ignatiadis
 
SMALL SIZE Europabio_report_print_
SMALL SIZE Europabio_report_print_SMALL SIZE Europabio_report_print_
SMALL SIZE Europabio_report_print_
cvpopa
 
Could ciat be(come) the latin-american convening centre on the knowledge ba...
Could ciat  be(come)  the latin-american convening centre on the knowledge ba...Could ciat  be(come)  the latin-american convening centre on the knowledge ba...
Could ciat be(come) the latin-american convening centre on the knowledge ba...
CIAT
 
Main figures biomedicine (Biopol'H)
Main figures biomedicine (Biopol'H)Main figures biomedicine (Biopol'H)
Main figures biomedicine (Biopol'H)
comunicaciobiopol
 
Funding opportunities for Food research and innovation
Funding opportunities for Food research and innovationFunding opportunities for Food research and innovation
Funding opportunities for Food research and innovation
Nikos Giannoulidis
 
Krommer j aw research-us-march2012
Krommer j   aw research-us-march2012Krommer j   aw research-us-march2012
Krommer j aw research-us-march2012
EUintheUS
 

Similar to Cdti biotech spain_juan_carlos_cortes (20)

Vertigeen stardard project presentation v final
Vertigeen stardard project presentation v finalVertigeen stardard project presentation v final
Vertigeen stardard project presentation v final
 
VERTIGEEN
VERTIGEENVERTIGEEN
VERTIGEEN
 
VERTIGEEN Project
VERTIGEEN ProjectVERTIGEEN Project
VERTIGEEN Project
 
Vertigeen stardard project presentation v final
Vertigeen stardard project presentation v finalVertigeen stardard project presentation v final
Vertigeen stardard project presentation v final
 
Juli Mylona - Bioconomy - plant science and agriculture. Future funding under...
Juli Mylona - Bioconomy - plant science and agriculture. Future funding under...Juli Mylona - Bioconomy - plant science and agriculture. Future funding under...
Juli Mylona - Bioconomy - plant science and agriculture. Future funding under...
 
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14
Les biotechnologies de santé en france 2014 vabrégée anglais 26 05 14
 
01 04 european union research and innovation perspectives on biotechnology
01 04 european union research and innovation perspectives on biotechnology01 04 european union research and innovation perspectives on biotechnology
01 04 european union research and innovation perspectives on biotechnology
 
Attracting EC Funding - Diana Salmen
Attracting EC Funding - Diana SalmenAttracting EC Funding - Diana Salmen
Attracting EC Funding - Diana Salmen
 
Genopole Crete Sept14 2007
Genopole  Crete Sept14 2007Genopole  Crete Sept14 2007
Genopole Crete Sept14 2007
 
SMALL SIZE Europabio_report_print_
SMALL SIZE Europabio_report_print_SMALL SIZE Europabio_report_print_
SMALL SIZE Europabio_report_print_
 
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectivesResearch and Innovation in Cardiovascular Diseases: The EU perspectives
Research and Innovation in Cardiovascular Diseases: The EU perspectives
 
Could ciat be(come) the latin-american convening centre on the knowledge ba...
Could ciat  be(come)  the latin-american convening centre on the knowledge ba...Could ciat  be(come)  the latin-american convening centre on the knowledge ba...
Could ciat be(come) the latin-american convening centre on the knowledge ba...
 
Main figures biomedicine (Biopol'H)
Main figures biomedicine (Biopol'H)Main figures biomedicine (Biopol'H)
Main figures biomedicine (Biopol'H)
 
20130710 Taller H2020 Sevilla EIP Agricultura: AMontero
20130710 Taller H2020 Sevilla EIP Agricultura: AMontero20130710 Taller H2020 Sevilla EIP Agricultura: AMontero
20130710 Taller H2020 Sevilla EIP Agricultura: AMontero
 
20130628 Taller H2020 Lleida EIP agricultura sostenible: AMontero
20130628 Taller H2020 Lleida EIP agricultura sostenible: AMontero20130628 Taller H2020 Lleida EIP agricultura sostenible: AMontero
20130628 Taller H2020 Lleida EIP agricultura sostenible: AMontero
 
Funding opportunities for Food research and innovation
Funding opportunities for Food research and innovationFunding opportunities for Food research and innovation
Funding opportunities for Food research and innovation
 
Philippe Amouyel, JPND Milan Nov. 2013
Philippe Amouyel, JPND Milan Nov. 2013Philippe Amouyel, JPND Milan Nov. 2013
Philippe Amouyel, JPND Milan Nov. 2013
 
Krommer j aw research-us-march2012
Krommer j   aw research-us-march2012Krommer j   aw research-us-march2012
Krommer j aw research-us-march2012
 
Ambient Assisted Living (AAL)-Joint Programme (JP)
Ambient Assisted Living (AAL)-Joint Programme (JP)Ambient Assisted Living (AAL)-Joint Programme (JP)
Ambient Assisted Living (AAL)-Joint Programme (JP)
 
Kassahun Tesfaye
Kassahun Tesfaye  Kassahun Tesfaye
Kassahun Tesfaye
 

More from BioAsia: The Global Bio Business Forum

More from BioAsia: The Global Bio Business Forum (19)

BioAsia Ms. Mandisa Hela - South Africa
BioAsia Ms. Mandisa Hela - South AfricaBioAsia Ms. Mandisa Hela - South Africa
BioAsia Ms. Mandisa Hela - South Africa
 
Drug Administration GoAP - Shri BL Meena
Drug Administration GoAP - Shri BL MeenaDrug Administration GoAP - Shri BL Meena
Drug Administration GoAP - Shri BL Meena
 
Myanmar Presentation - BioAsia 2013
Myanmar Presentation - BioAsia 2013Myanmar Presentation - BioAsia 2013
Myanmar Presentation - BioAsia 2013
 
Prof. Juozas Galdikas Lthuania - BioAsia 2013
Prof. Juozas Galdikas Lthuania - BioAsia 2013Prof. Juozas Galdikas Lthuania - BioAsia 2013
Prof. Juozas Galdikas Lthuania - BioAsia 2013
 
A Wider Role for Statisticians in Biopharmaceutical Industry
A Wider Role for Statisticians in Biopharmaceutical IndustryA Wider Role for Statisticians in Biopharmaceutical Industry
A Wider Role for Statisticians in Biopharmaceutical Industry
 
How to start a discovery based R&D company in India?
How to start a discovery based R&D company in India?How to start a discovery based R&D company in India?
How to start a discovery based R&D company in India?
 
SOME HEALTHY CYNICISM REGARDING NANOMETER-SIZED DRUG AND ANTIGEN DELIVERY SY...
SOME HEALTHY CYNICISM REGARDING NANOMETER-SIZED DRUG AND ANTIGEN DELIVERY SY...SOME HEALTHY CYNICISM REGARDING NANOMETER-SIZED DRUG AND ANTIGEN DELIVERY SY...
SOME HEALTHY CYNICISM REGARDING NANOMETER-SIZED DRUG AND ANTIGEN DELIVERY SY...
 
Application of the embryonic stem cell model for drug discovery and developme...
Application of the embryonic stem cell model for drug discovery and developme...Application of the embryonic stem cell model for drug discovery and developme...
Application of the embryonic stem cell model for drug discovery and developme...
 
Hematopoietic Stem Cell Transplantation : Opportunities and challenges
Hematopoietic Stem Cell Transplantation : Opportunities and challengesHematopoietic Stem Cell Transplantation : Opportunities and challenges
Hematopoietic Stem Cell Transplantation : Opportunities and challenges
 
Cellular Therapies (Including Stem Cell treatment) for Human SCI
Cellular Therapies (Including Stem Cell  treatment) for  Human SCICellular Therapies (Including Stem Cell  treatment) for  Human SCI
Cellular Therapies (Including Stem Cell treatment) for Human SCI
 
VACCINES: India’s Strength
VACCINES: India’s StrengthVACCINES: India’s Strength
VACCINES: India’s Strength
 
Rushing to Outsource Pharmaceutical R&D to India? Consider a host Intellectua...
Rushing to Outsource Pharmaceutical R&D to India? Consider a host Intellectua...Rushing to Outsource Pharmaceutical R&D to India? Consider a host Intellectua...
Rushing to Outsource Pharmaceutical R&D to India? Consider a host Intellectua...
 
Transfer of novel academic research in vaccines into marketable products – a ...
Transfer of novel academic research in vaccines into marketable products – a ...Transfer of novel academic research in vaccines into marketable products – a ...
Transfer of novel academic research in vaccines into marketable products – a ...
 
Renaissance ctsi at BioAsia
Renaissance ctsi at BioAsiaRenaissance ctsi at BioAsia
Renaissance ctsi at BioAsia
 
Importance of Pharmacovigilance for a Biotechnology company
Importance of Pharmacovigilance for a Biotechnology companyImportance of Pharmacovigilance for a Biotechnology company
Importance of Pharmacovigilance for a Biotechnology company
 
Accelerator overview at BioAsia
Accelerator overview at BioAsiaAccelerator overview at BioAsia
Accelerator overview at BioAsia
 
Current issues and trends in Seed Industry, BioAsia 2010
Current issues and trends in Seed Industry, BioAsia 2010Current issues and trends in Seed Industry, BioAsia 2010
Current issues and trends in Seed Industry, BioAsia 2010
 
Agribiotech R&D in Private sector
Agribiotech R&D in Private sectorAgribiotech R&D in Private sector
Agribiotech R&D in Private sector
 
Bioasia2010
Bioasia2010Bioasia2010
Bioasia2010
 

Cdti biotech spain_juan_carlos_cortes

  • 1. The Spanish Biotech sector in figures Juan Carlos Cortés International Director Centre for the Development of Industrial Technology Ministry of Economy & Competitiveness UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 1 (07/02/2013) Una manera de hacer Europa
  • 2. The Spanish Biotech sector • A young sector, 15 years old. • Internationalization is part of its DNA. • Success depends on the capacity to export. • Crucial: joint projects and technology exchange agreements. Spain: • Biotech industry growth in the last four years 350% • A key player in R&D, spin-offs, research and collaboration. • Biotech: a key sector in the knowledge economy UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 2 (07/02/2013) Una manera de hacer Europa
  • 3. The Spanish Biotech sector now Source: Genoma España/ASEBIO • Nº enterprises: 1.715 (617 EB+1.098 EIB) • Nº personnel employed EB1+EIB2: 163.526 • Estimated turnover EB (2010): 60.122 MM€ • Internal expenditures in R&D: 568.280 M€ (11,2% increase from 2009) • Enterprises related to human health: 67% • Enterprises related to agro-food: 23% • Enterprises related to industrial processing: 10% 1EB: biotechology enterprise 2EIB:industrial commercial or services’ enterprise, with interests, develpments and products in biotechnology UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 3 (07/02/2013) Una manera de hacer Europa
  • 4. Contribution of Biotechnology to the Spanish economy Contribution to GDP 2010 (%) 1,2 GDP Contribution Employment Macroeconomic impact of biotechnology OECD prediction GDP 2030 (%) 2,7 Contribution to GDP (%) Predicted contribution to GDP (%) Employment Predicted employment UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 4 (07/02/2013) Una manera de hacer Europa
  • 5. Classification of Bio-companies Agriculture Food Animal Health Environment Human Health UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 5 (07/02/2013) Una manera de hacer Europa
  • 6. Profile of the Biotechnology enterprise (EB) in Spain • Between 10 and 20 employees • Over 80% of the staff university graduates • Over 25% of the staff devoted to R&D • Less than 5 years of activity • Located mostly in Madrid, Barcelona, Andalucía, País Vasco and Valencia • Linked to prestigious public research institutions UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 6 (07/02/2013) Una manera de hacer Europa
  • 7. Spain: eight Bioregions UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 7 (07/02/2013) Una manera de hacer Europa
  • 8. The Spanish Biotech sector : scientific production (00-08) Source: Genoma España European contribution to world scientific production European contribution to world scientific in biosciences (2000) production in biosciences (2008) United Kingdom Germany Germany United Kingdom France France Italy Italy Netherlands Spain Spain Netherlands Sweden Sweden Belgium Denmark Denmark Belgium Finland Austria Austria Finland Ireland Portugal Portugal Ireland Greece Greece Luxembourg Luxembourg UNIÓN EUROPEA Growth: 47% (annual rate 6%) Fondo Europeo de Desarrollo Regional (FEDER) 8 (07/02/2013) Una manera de hacer Europa
  • 9. The Biotech sector in Spain: evolution of the nº of enterprises (00-08) Source: Genoma España Evolution of EB and EIB UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 9 (07/02/2013) Una manera de hacer Europa
  • 10. The biotech sector in Spain: total public expenditures on R&D&I biotech Source: Genoma España Total public support for R&D&I in Biotechnology (Mio €) UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 10 (07/02/2013) Una manera de hacer Europa
  • 11. Success stories - 2000: Pfizer invested 12m euros in its European Biometric Centre, which has support functions for the rest of Europe and USA. - 2002: Abengoa signed a 35.5million dollar R&D Agreement with the US Department of Energy. - 2002: Lilly opened its research centre for medicinal chemistry, one of the biggest in the world, investing 20 million euros. - 2003: Serono concentrates its global growth-hormone production in Spain. - 2005: GSK opens its research centre for tropical diseases in Spain. - 2009: Genzyme sets up a sales office in Madrid and has a warehouse for domestic distribution. - 2011: Celgene opens its first research centre outside the USA in Seville. The Celgene Institute of Translational Research Europe (CITRE) plans to focus on advanced therapies and regenerative medicine. UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 11 (07/02/2013) Una manera de hacer Europa
  • 12. Spanish Technology Platforms • Biotech Markets • Nanomedicine www.nanomedspain.net/ • Innovative Medicines www.medicamentos- innovadores.org/ • Plants Biotechnology www.invigen.org • Animal Health www.vetmasi.es UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 12 (07/02/2013) Una manera de hacer Europa
  • 13. CDTI DATA 2011 RTD Project Nr .of funded CDTI funding Total and NEOTEC companies investment 92 M€48,116 M€ 64,6 INNPRONTA Nr. of funded CDTI funding Total call companies investment (2 Projects) 17 M€ 27,67 M€ 32,56 Indo-Spanish Nr. of proposals Selected call CDTI-DBT projects First call 2012 7 3 UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 13 (07/02/2013) Una manera de hacer Europa
  • 14. Potential areas for cooperation SPANISH TECHNOLOGICAL STRENGTHS Health and Nano biotechnology Some Developments in 2011 • Oncology,: Advancell, GP Pharm, Ingenasa, Pharmamar, IUCT, Lipopharma, Entrechem, Orizon Genomics • Cardiology/ Neurological: Neuron Pharma, Sanifit, • Oftalmology: Sylentis, Proretina Therapeutics, Biotechnology Institute, Bioftalmic • Vaccines: Archivel Farma, Ferrer, Rovi, Leti • Biotech diagnosis, biomarkers, nanomedicine: Orizon Genomics, Sistemas Genomicos, AB BIOTICs, Genomica, Biobide, Pangaea Biotech, Genetadi Botech, Aromics, Nanotherapy, Nanoinmunotech… • Animal Health: Bionaturis, Ingenasa • Bioinformatic: Integromics, Noray Bio, Biomol Informatics • Regenerative medicine, Cell and Gene therapy: Tigenics (former Cellerix) • Biofuels: Abengoa, Repsol 4th Nano biotechnology Scientific production in the world • Barcelona the 2nd Nano biotech city (1st Boston) UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 14 (07/02/2013) Una manera de hacer Europa
  • 15. Institutions supporting the sector in Spain: Promoting value creation through knowledge www.asebio.com • ASEBIO is the Spanish Asociation of Biocompanies • ASEBIO belongs to and is supported by EUROPABIO, and is a part of CEOE and SEBBM UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 15 (07/02/2013) Una manera de hacer Europa